Alchemia Release: Key Fondaparinux Patent Allowed by U.S. Patent Office  
10/21/2008 10:58:42 AM

BRISBANE, Australia--(BUSINESS WIRE)--Australian drug developer Alchemia Limited (ASX:ACL) today announced it had received a ‘notice of allowance’ for the United States patent application titled Synthetic Heparin Pentasaccharides (number 10/488,677). A notice of allowance is a notification to the patent applicant that they are entitled to a patent under the law and is issued for applications that have been filed based on "intent to use." The patent number will be assigned on payment of the grant fees.